Gland Pharma to infuse Rs 400 crore to expand Genome Valley facility
Rama Rao said,"I am delighted that Gland Pharma will be investing Rs 400 crores in expanding their footprint in Hyderabad and will create 500 more jobs in Telangana."
New Delhi: Gland Pharma has announced that it would be investing Rs 400 crore to create additional capabilities in its existing facility at Genome Valley here to manufacture biologicals, biosimilar, antibodies and recombinant Insulin.
An official release from the state government said the expanded facility will have employment generation potential of more than 500 numbers of qualified, skilled and semi-skilled workforce to be recruited, mostly from the nearby places.
The company had established their biopharmaceutical facility in February last year at Genome Valley with an investment of Rs 300 crore to manufacture vaccines, biologicals, biosimilar, antibodies and others.
The expanded site is envisaged to meet the national and international regulations to be followed in the manufacturing of the biological products as applicable and shall be built under the GMP guidelines applicable for the respective product lines, it said.
The announcement was made after Telangana Industries Minister KT Rama Rao's meeting with the Managing Director and Chief Executive Officer of Gland Pharma Srinivas Sadu.
Srinivas Sadu said, "We are delighted to collaborate with the Government of Telangana on its vision of making the State a hub for global pharmaceutical requirements, by expanding our Bio-CDMO facilities in Shamirpet. This project investment is estimated to be about Rs 400 crore and expected to generate employment to about 500 personnel."
Rama Rao said, "I am delighted that Gland Pharma will be investing Rs 400 crores in expanding their footprint in Hyderabad and will create 500 more jobs in Telangana."
Gland Pharma was established in Hyderabad, India, in 1978. The company is present in sterile injectables, oncology and ophthalmic segments, and focuses on complex injectables including NCE-1s, First-to-File products and 505(b)(2) filings. Its products are delivered via liquid vials, lyophilized vials, pre-filled syringes, ampoules, bags and drops.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.